Présentation

Sujets de recherche

Diabetes, Metabolic Disorders.

Disciplines de recherche

Cell Biology, Endocrinology.

Mots-clés

Animal model, Atherosclerosis, Cytokines, Diabetes, Endothelium, Growth factors, Mollecular cell biology, Phosphatase, PKC, Vascular cell biology.

Intérêts de recherche

I intent to better understand the mechanisms related to vascular complications in diabetes. I have made a very interesting finding that growth factor deficiency or resistance by the protein tyrosine phosphatase SHP-1 can cause cell apoptosis and contribute to early changes in diabetic retinopathy. The goal of my research is to investigate potential target of SHP-1 and other protein tyrosine phosphatases in vascular complications of diabetes such as diabetic nephropathy, peripheral arterial diseases and atherosclerosis.

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français, Portuguais

Prix et distinctions

• (2022) Canadian Research Chair Tier II. Canadian Institutes of Health Research. (Distinction).
• (2016) Canadian Diabetes Association Scholar Award. Canadian Diabetes Association. (Prize / Award).
• (2012) Young Scientist Scholar Award. Fonds de recherche du Québec - Santé (FRQS). (Prize / Award).
• (2010) Advanved Postdoctoral Award. Juvenile Diabetes Research Foundation. (Prize / Award).
• (2009) Postdoctoral Award. Fonds de recherche du Québec - Santé (FRQS). (Prize / Award).
• 2017 Young Investigator Award. FRQS CardioMetabolic, Diabetes and Obesity (CMDO) Network. (Prize / Award).

Financement

Grant. (Awarded). Principal Applicant. Phosphatases and mechanisms of poor collateral vessel formation in diabetes. Canadian Institutes of Health Research (CIHR). Project Grant. 753526 $ (2018-2023).

Grant. (Awarded). Principal Applicant. Mechanisms of insulin resistance in podocytes and diabetic nephropathy. Canadian Institutes of Health Research (CIHR). Project grant. 677025 $ (2017-2022).

Grant. (Awarded). Principal Applicant. Evaluation of SHP-1 expression in podocyturia of diabetic patients.. Fondation Diabète Brome-Missisquoi. Biomedical Grant. 50000 $ (2016-2019).

Grant. (Awarded). Principal Applicant. Role of IGFBP-2 on podocyte injury and type 2 diabetic nephropathy. CMDO network FRQ-S. Inter center project grant. 40000 $ (2018-2019).

Grant. (Completed). Principal Investigator. Live-cell perfusion imaging to study vascular complications of diabetes. Canada Foundation for Innovation (CFI). John-R.-Evans Leader Funds. 230437 $ (2014).

Publications

Articles de revue

• Robillard S.*, Mercier C.*, Breton V.*, Paquin-Veillette J.*, Guay A., Lizotte L. and Geraldes P. (2019). Ablation of AT2 receptor prevents eNOS glutathionylation and nitration in ischemic abductor muscle of diabetic mice. Diabetes Vascular Disease Research, DOI. (Accepted).
• Lacroix M., Lizotte F., Hivert M-F., Geraldes P.*, Perron P*. *Co-Senior Authors. (2019). Calcifediol decreases interleukin-6 secretion by cultured human trophoblasts from GDM pregnancies. Journal of the Endocrine Society, 3(11), 2165-78. DOI. (Accepted).
• Denhez B.*, Rousseau M.*, Dancosst D-A*, Lizotte F., Guay A., Auger-Messier M., Côté A-M. and Geraldes P. (2019). Diabetes-induced DUSP4 reduction promotes podocyte dysfunction and progression of diabetic nephropathy. Diabetes, 68(5), 1026-1039. (Accepted).
• Quiroga D.T., Miquet J.G., Gonzalez L., Sotelo A.I., Muñoz M.C., Geraldes P.M., Giani J.F., Dominici F.P. (2019). Mice Lacking angiotensin type 2 receptor exhibit a sex-specific attenuation of insulin sensitivity. Mollecular and Cellular Endocrinology, 498, 110587. DOI. (Accepted).
• Barrière D.A., Noll C., Roussy G., Lizotte F.*, Kessai A., Kirby K., Belleville K., Beaudet N., Longpre J-M., Carpentier A.C., Geraldes P, Sarret P. (2018). Combination of high-fat/high-fructose diet and low-dose streptozotocinto model long-term type-2 diabetes complications. Scientific Report, 8(1), 424. (Accepted).
• Geraldes, Pedro. (2018). Protein Phosphatase and Podocyte Function. Current Opinion in hypertension and nephropathy, 27(1), 49-55. (Accepted).
• Lacroix M., Lizotte F., Hivert M-F., Geraldes P.*, Perron P.*. (2017). Calcifediol stimulation decreases interleukin-6 secretion by cultured human trophoblasts from GDM pregnancies. Endocrinology, *co-last author, (Submitted).
• Paquin-Veillette J.*, Lizotte F., Robillard S.*, Béland R.*, Breton, M-A.*, Despatie M-A., Geraldes P. (2017). Deletion of AT2 receptor prevents SHP-1 causing VEGF inhibition and improves blood flow reperfusion in diabetic ischemic hindlimb. ATVB, 37(12), 2291-2300. (Accepted).
• Denhez, B.* Geraldes, P. (2017). Regulation of Nephrin Phosphorylation in Diabetes and Chronic Kidney Injury. Adv Exp Med Biol, 966, 149-161. (Accepted).
• Lizotte F.*, Denhez B.*, Guay A., Gévry N., Côté AM and Geraldes P. (2016). Persistent insulin resistance in podocytes caused by epigenetic changes of SHP-1 in diabetes. Diabetes, 65(12), 3705-17. (Accepted).
• Denhez D.*, Lizotte F.*, Guimond M-O., Jones N., Takano T., Geraldes P. (2015). Increased SHP-1 expression by high glucose levels reduced nephrin phosphorylation in podocytes. The Journal of biological chemistry, 390(1), 350-8. (Accepted).
• Durpès M-C.*, Morin C.*, Paquin-Veillette J.*, Béland R.*, Paré P.*, Guimond M-O., Rekhter M., King GL., Geraldes P. (2015). PKC beta activation inhibits interleukin-18 binding protein causing endothelial dysfunction and accelerated diabetic atherosclerosis. Cardiovascular Research, 106(2), 303-13. (Accepted).
• Drapeau N.*, Lizotte F.*, Denhez B.*, Guay A., Kennedy CR., Geraldes P. (2013). Expression of SHP-1 induced by hyperglycemia prevents insulin actions in podocytes. American journal of physiology. Endocrinology and metabolism, 304(11), E1188-98. (Accepted).
• Lizotte F.*, Paré M.*, Denhez B.*, Leitges M., Guay A., Geraldes P. (2013). PKC? Impaired Vessel Formation and Angiogenic Factor Expression in Diabetic Ischemic Limbs. Diabetes, 62(8), 2948-57. (Accepted).
• Mima A., Kitada M., Geraldes P., Li Q., Matsumoto M., Mizutani K., Qi W., Li C., Leitges M., Rask-Madsen C., King GL. (2012). Glomerular VEGF resistance induced by PKC?/SHP-1 activation and contribution to diabetic nephropathy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 26(7), 2963-74. (Accepted).
• Mima A., Hiraoka-Yamomoto J., Li Q., Kitada M., Li C., Geraldes P., Matsumoto M., Mizutani K., Park K., Cahill C., Nishikawa S., Rask-Madsen C., King GL. (2012). Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKC? activation in diabetes. Diabetes, 61(11), 2967-79. (Accepted).
• Mima A., Ohshiro Y., Kitada M., Matsumoto M., Geraldes P., Li C., Li Q., White GS., Cahill C., Rask-Madsen C., King GL. (2011). Glomerular-specific protein kinase C-?-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney international, 79(8), 883-96. (Accepted).
• Geraldes P , King GL. (2010). Activation of protein kinase C isoforms and its impact on diabetic complications. Circulation research, 106(8), 1319-31.
• Rask-Madsen C , Li Q , Freund B , Feather D , Abramov R , Wu IH , Chen K , Yamamoto-Hiraoka J , Goldenbogen J , Sotiropoulos KB , Clermont A , Geraldes P , Dall'Osso C , Wagers AJ , Huang PL , Rekhter M , Scalia R ,. (2010). Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell metabolism, 11(5), 379-89. (Accepted).
• Geraldes P , Hiraoka-Yamamoto J , Matsumoto M , Clermont A , Leitges M , Marette A , Aiello LP , Kern TS , King GL. (2009). Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nature medicine, 15(11), 1298-306.
• Kondo T , El Khattabi I , Nishimura W , Laybutt DR , Geraldes P , Shah S , King G , Bonner-Weir S , Weir G , Sharma A. (2009). p38 MAPK is a major regulator of MafA protein stability under oxidative stress. Molecular endocrinology (Baltimore, Md.), 23(8), 1287-90.
• Geraldes P , Geoffroy P , Cloutier I , Sirois MG , Tanguay JF. (2008). Local delivery of 17-beta-estradiol modulates collagen content in coronary porcine arteries after PTCA and stent implantation. Journal of vascular research, 45(6), 503-11.
• Geraldes P , Yagi K , Ohshiro Y , He Z , Maeno Y , Yamamoto-Hiraoka J , Rask-Madsen C , Chung SW , Perrella MA , King GL. (2008). Selective regulation of heme oxygenase-1 expression and function by insulin through IRS1/phosphoinositide 3-kinase/Akt-2 pathway. The Journal of biological chemistry, 283(49), 34327-36.
• Geraldes P , Yamagata M , Rook SL , Sassa Y , Ma RC , Clermont A , Gao B , Aiello LP , Feener EP , King GL. (2007). Glypican 4, a membrane binding protein for bactericidal/permeability-increasing protein signaling pathways in retinal pigment epithelial cells. Investigative ophthalmology & visual science, 48(12), 5750-55.
• Geraldes P , Gosselin H , Tanguay JF , Clément R , Calderone A. (2007). Tamoxifen treatment of myocardial infarcted female rats exacerbates scar formation. Pflügers Archiv : European journal of physiology, 454(3), 385-93.
• Yamagata M , Rook SL , Sassa Y , Ma RC , Geraldes P , Goddard L , Clermont A , Gao B , Salti H , Gundel R , White M , Feener EP , Aiello LP , King GL. (2006). Bactericidal/permeability-increasing protein's signaling pathways and its retinal trophic and anti-angiogenic effects. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 20(12), 2058-67.
• Geraldes P , Gagnon S , Hadjadj S , Merhi Y , Sirois MG , Cloutier I , Tanguay JF. (2006). Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ERalpha-mediated pathway. Cardiovascular research, 71(3), 566-73.
• Gagnon C , Legault F , Geraldes P , Tanguay JF , Lambert C. (2004). Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. International journal of cardiology, 97(3), 373-81.
• Geraldes P , Sirois MG , Tanguay JF. (2003). Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circulation research, 93(5), 399-405.
• Geraldes P , Sirois MG , Bernatchez PN , Tanguay JF. (2002). Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arteriosclerosis, thrombosis, and vascular biology, 22(10), 1585-90.

Articles de conférence

• Lizotte F., Geraldes P. (2017). Deletion of SHP-1 Specifically in Smooth Muscle Cells Restores PDGF Action in Diabetes. Diabetes Canada Professional Conference and Annual Meeting. (Accepted).
• Denhez B., Rousseau M., Lizotte F., Auger-Messier M., Côté A-M., Geraldes P. (2017). Loss of DUSP4 promotes insulin resistance in podocytes through JNK activatLoss of DUSP4 promotes insulin resistance in podocytes through JNK activation. American Society of Nephrology. (Accepted).
• Dumas M-E., Denhez B., Lizotte F., Geraldes P. (2017). Mechanisms of Insulin Resistance induced by FFA inRenal Podocytes Leading to Diabetic Nephropathy. American Diabetes Association. (Accepted).
• Robillard S., Lizotte F., Guay A., Geraldes P. (2017). Reduction of DUSP4 Exacerbates Blood Flow Reduction in Diabetes. Diabetes Canada Professional Conference and Annual Meeting. (Accepted).
• Denhez B., Lizotte F., Guay A., Geraldes P. (2016). Role of DUPS4 in kidney complications of diabetes. Canadian Diabetes Association/CSEM annual professional conference. (Published).
• Paquin-Veillette J., Guay A., Geraldes P. (2015). Deletion of AT2 Receptor Prevents SHP-1 Expression and Improves Blood Flow in Diabetic Ischemic Hindlimb. American Heart Association. (Published).
• Lizotte F., Denhez B., Guay A., Geraldes P. (2015). Deletion of SHP-1 in Podocytes Prevents Diabetic Nephropathy. American Society of Nephrology Kidney Week. (Published).
• Lizotte F., Denhez B., Guay A., Geraldes P. (2015). Hyperglycemic Memory in DN: Effects of Epigenetic Changes of SHP-1 in Podocytes. American Society of Nephrology Kidney Week. (Published).
• Denhez B., Lizotte F., Guay A., Geraldes P. (2015). Role of DUPS4 inDiabetic Nephropathy. American Society of Nephrology Kidney Week. (Published).
• Pare M., Guimond M-O., Geraldes P. (2014). Activationby Hyperglycemia Inhibits PDGF’s Pro-Angiogenic Effects in Hypoxic SmoothMuscle Cells. Canadian Diabetes Association/CSEM annual professional conference. (Published).
• Lizotte F., Denhez B., Guimond M-O., Geraldes P. (2014). Hyperglycemic memory indiabetes nephropathy: potential role of SHP-1. Canadian Diabetes Association/CSEM annual professional conference. (Published).
• Lizotte F., Denhez B., Kennedy C.R., Guimond M-O., Geraldes P. (2013). Glycemic Memory in Diabetes Nephropathy, Potential Role Of SHP-1. American Society of Nephrology Kidney Week. (Published).
• Denhez B., Lizotte F., Kennedy C.R., Guimond M-O., Geraldes P. (2013). Inhibition of Nephrin Signaling by SHP-1 in Diabetic Nephropathy. American Society of Nephrology Kidney Week. (Published).
• Denhez B., Lizotte F., Guimond M-O., Geraldes P. (2013). New Mechanism for Podocyte Dysfunction: Regulation of Nephrin by SHP-1. Vascular 2013. (Published).
• Geraldes P. (2013). Targeting Protein Kinase C in the vessel wall: newperspectives. Cardiometabolic Risk and Vascular Diseases Symposium: European Society of Cardiology. (Published).
• Durpes M-C., Morin C., Guimond M-O. Geraldes P. (2013). The dysregulation of Interleukin-18 pathway: a potentiallink between hyperglycemia and the accelerated atherosclerosis in diabetes. Vascular 2013. (Published).
• Durpes M-C., Geraldes P. (2013). The dysregulation of Interleukin-18 pathway: a potential link between hyperglycemia and the accelerated atherosclerosis in diabetes. European Atherosclerosis Society. (Published).
• Drapeau N., Lizotte F., Geraldes P. (2012). Hyperglycemia-induced SHP-1 causes insulinresistance in podocytes. American Diabetes Association conference. (Published).
• Drapeau N., Lizotte F., Geraldes P. (2012). Hyperglycemia-induced SHP-1 expression leads toinhibition of insulin actions and podocyte apoptosis. Canadian Nephrology Society. (Published).
• Pare M., Guay A., Geraldes P. (2012). PKC Activation RegulatesInsulin Action in Vascular Smooth Muscle Cells: Potential Mechanism for PoorCollateral Vessel Formation in Diabetes. Canadian Diabetes Association/CSEM annual professional conference. (Published).
• Mima A., Munehiro K., Geraldes P., Li Q., Qi W., Mizutani K., Rask-Madsen C., King G.L. (2011). Hyperglycemia Induced Inactivation of VEGF byPKC?/SHP-1: A Cause for Podocyte Apoptosis in Diabectic Nephropathy. American Diabetes Association conference. (Published).

Propriétés intellectuelles

Patents

• Methods of Modulating Metabolic Memory. 10276-112W01. United States. (Granted/Issued).

Autres contributions

Cours enseignés

• (2012-04-11 à 2012-04-11). Niveau : Graduate. (2CR).
• (2012-01-12 à 2012-05-23). Niveau : Graduate. (2CR).

Gestion d'évènements

• Organizer. Scientific Day of the Diabetes, Obesity and Cardiovascular Complications (DOCC) team group. (Seminar).

Présentations

• (2019). Role of phosphatase in peripheral arterial and chronic kidney diseases in diabetes. CardioMetabolic, Diabetes and Obesity Annual Meeting. Offord, Canada.
• (2017). Mechanisms of insulin resistance in podocytes and diabetic nephropathy. CRCHUM - MUHC Nephrology Conference. Canada.
• (2017). Protecting factor inhibition and vascular complications of diabetes. Indiana University School of Public Health-Bloomington. United States.
• (2016). Essentials for Preparing a Career in Diabetes and Endocrine Research. CDA/CSEM Professional Conference. Ottawa, Canada.
• (2016). Vascular complication of diabetes. Signalisation Québec 2016. Trois-Rivières, Canada.
• (2013). Diabetes and cardiovascular complications: the quest to find new markers. Conference series - Montreal Heart Institute. Montreal, Canada.
• (2013). Glycemic memory in diabetic nephropathy: the quest to find new mechanisms. CHUM-MUHC Nephrology Conference. Montreal, Canada.
• (2013). Inhibition of the Protecting Factors: New Mechanism of Vascular Complications in Diabetes. IRCM Cardiometabolite Disease Seminar Series. MONTREAL, Canada.
• (2013). Insulin regulation in podocytes and diabetic nephropathy. University of Toronto CityWide Endocrine Rounds. Toronto, Canada.
• (2013). New Mechanisms for metabolic legacy effect in diabetic nephropathy. Kidney Research Centre (KRC) Journal Club rounds. Ottawa, Canada.
• (2013). Targeting Protein Kinase C in the vessel wall: new perspectives. 2e symposium Cardiometabolic Risk and Vascular Diseases – from Mechanisms to Treatment. Rome, Italy.
• (2013). Vascular complications of diabetes: why there is no treatment yet?. BioMed Research Center. Montreal, Canada.
• (2011). Diabetes and Vascular Complications: Beyond Oxidative Stress. Endocrinology/Nutrition/Renal Diseases. Canada.
• (2010). Hyperglycemia-induced apoptosis – a NF-?B independent pathway. Signalisation Quebec 2010. Offord, Canada.